Global Metabolomics Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report - By Product (Metabolomic Bioinformatics, Metabolomic Tools and Services), Indication, Application & Region – Industry Forecast (2024 to 2029)

Updated On: January, 2024
ID: 3318
Pages: 175

Global Metabolomics Market Size (2024 to 2029)

As per our research report, the size of the global metabolomics market is estimated to grow to USD 7116.44 million by 2029 from USD 2744.07 million in 2024, growing at a CAGR of 19% during the forecast period.

Metabolomics is the substantial scale research of little atoms, ordinarily known as metabolites, inside cells, biofluids, tissues, or living beings. Aggregately, these tiny particles and their associations inside an organic framework are known as the metabolome. Metabolomics is a capable approach since metabolites and their concentration, unlike other "omics" measures, straightforwardly reflect cells/tissues' hidden biochemical movement and condition of cells/tissues. Consequently, metabolomics represents the atomic phenotype. Consequently, the global Metabolomics market is developing at a rapid pace.


The developing acceptance of metabolomics in personalized medicines is one of the key variables boosting the global metabolomics market growth.

The expanding biotech innovative work and pharmaceutical consumption prompt persistent headways in innovation and spelling development for the worldwide metabolomics market. Then again, there are issues concerning information handling and information examination, representing a test for the market. Increasing demand for personalized medicines is expected to boost the growth opportunities for the metabolomics market. Furthermore, the increasing frequency of chronic degenerative diseases like cancer, cardiovascular diseases, and neurological disorders is likely to offer lucrative growth opportunities for the growth of the global metabolomics market. Furthermore, increasing economies of developing countries such as China, India, Brazil, and the Middle East will likely offer key stakeholders opportunities. In addition, the emergence of novel and innovative products due to technological developments immensely biomarkers contributes to the market's growth. Therefore, it is anticipated to create more opportunities for the growth of the world metabolomics market during the forecast period.


The high cost of instruments and devices is expected to hamper the global metabolomics market's growth rate slightly.

Further, the requirement for very much qualified specialists and the absence of the same limits the development of the metabolomics market. But, be that as it may, the undiscovered markets in rising countries will goad new development open doors for market players.

Impact of COVID-19 on the global metabolomics market

The SARS-CoV-2 reagent caused the new coronavirus (COVID-19) to affect millions of human lives, causing death, and the world has been brought to a standstill. Therefore, metabolomics plays an important role and is highly informative in clinical research. The main target for metabolomics-based COVID-19 research is recognizing the biomarker signatures and permitting clinicians to predict the therapeutic response. The SARS-CoV-2 virus is all biological material composed of all metabolites, lipids, proteins, and other small molecules. COVID-19 patients are described by the standard plasma metabolomic and lipidomic signatures. The researchers use the combination of metabolomics and machine learning to recognize the possible biomarkers, which helps determine COVID-19 and analyze the risk of developing a critical illness. The pandemic has prominently impacted the global life sciences instruments market. The pandemic crisis has observed a short-term negative growth over the need for mass spectrometry and chromatography instruments used in metabolomics research. The negative change in the global metabolomics market is diminishing product demand in the end-users, an interrupted supply chain, and insufficient funds to research and academic institutes. Furthermore, the pandemic has produced the temporary closure of different laboratories and research centers worldwide. Considering the present situation, the pharma and biotech industries prevent the virus from spreading by offering necessary drugs, vaccine kits, and other supplies.




Market Size Available

2024 to 2029

Base Year


Forecast Period

2024 to 2029

Segments Covered

By Technology, Product, and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Covered

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

Market Leaders Profiled

Agilent Technologies, Inc. (U.S.), Human Metabolome Technologies, Inc. (Japan), Thermo Fisher Scientific, Inc. (U.S.), LECO Corporation (U.S.), Bruker Corporation (U.S.), Shimadzu Corporation (Japan), Metabolon Inc. (U.S.), Danaher Corporation (U.S.).


Metabolomics Market - By Product

Based on the product, the metabolomics instruments segment is forecasted to be the most lucrative segment among all in the global metabolomics market, and it has contributed the highest share. The adoption of metabolomics is increasing rapidly due to smooth technological operations leading to high workflow efficiency. In addition, other factors, such as reliability, precision, and data processing, are highly transparent and propel the growth of the metabolomics instruments segment.

Metabolomics Market - By Application

Based on the Application, the biomarker discovery segment has contributed a significant share in the overall revenue of the world metabolomics market. It is expected to be a rapidly growing segment among the applications during the forecast period. The adoption of metabolic biomarkers is consistently increasing for controlling diseases at the metabolic level due to enhanced reliability and efficiency, eventually leading to the growth of the biomarker discovery market. Furthermore, collaborations between biotechnology firms and pharmaceutical companies to validate and discover biomarkers are likely to propel the development of the personalized medicine segment during the forecast period.


Geographically, the metabolomics market in North America was dominating in 2023, which comprises the United States and Canada. The existence of major participants in the metabolomics industry in the United States, growing biomedical research in the United States, and growing preclinical activities by CROs and pharmaceutical companies in the region all contribute to the region's prominent position. In addition, the presence of high per capita healthcare expenditures, rising adoption rates of healthcare technology, a well-established direct sales channel across the region, and a continuous boost to small and mid-sized metabolomics-oriented research communities and companies from the National Institutes of Health (NIH) program, all contribute to the metabolomics industry's growth. In the future, metabolomics is anticipated to enhance drug discovery and customized therapy, particularly in high-demand illness areas, including cardiovascular and metabolic disorders, cancer, mental health, and other infectious diseases. High product commercialization rates and advanced healthcare-related research and development activities are some of the causes contributing to the company's substantial market share.

The metabolomics market in Europe is estimated to grow at a CAGR of 18.4% during the forecast period and worth USD 2060 Million by 2029. Govt. financing and private funding are also reassuring the growth of this market. Metabolomics has gradually sought after as they help in shrinking the hole between genotype and phenotype by offering a whole perspective of the cell working. Stable, innovative advances and looks into will guarantee a proceeded with the development of this market and decrease these restrictions' effect in the future. Nonetheless, the unexplored markets in evolving countries will spur new progress open doors for market players.

The metabolomics market in the Asia Pacific is the second-largest region, owing to the growing demand for improved pharmaceutical goods from developing economies such as India and China, one of the market's most significant growth contributors. Because of key players in the Metabolomics Market, the Asia Pacific region is anticipated to expand at a significant CAGR during the forecast period. In addition, the rising aging population and rising instances of a wide range of illnesses have created possibilities for pharmaceutical firms in the area, propelling the metabolomics industry in the Asia Pacific region. Other factors contributing to market expansion in the Asia-Pacific region include growing demand for healthcare facilities, enhanced healthcare, and investments in life sciences that have opened up new avenues for market growth. Furthermore, mergers and partnerships between different government entities in terms of R&D efforts in metabolomics are taking place in nations like India. Additionally, both private and governmental entities have increased their investments. These factors are expected to have a favorable influence on India's metabolomics market growth.

In places like Australia, there has been an increase in healthcare spending. Furthermore, Australia has well-established infrastructure and expanding access to high-end technology in several industries. As a result, these factors are expected to enhance the metabolomics market growth in Australia.

The metabolomics market in Latin America has been estimated at USD 232.01 Million in 2024 and worth USD 577.85 Million by 2029. Govt. subsidizing is moreover reassuring the development of this market. Metabolomics is in effect progressively sought after as they help reduce the hole amongst genotype and phenotype by offering a total perspective of the cell working. It additionally helps in the recognizable proof of novel changes in a portion of the metabolites. The market is anticipated to keep thriving in both created and created districts. The development is additionally credited to the developing interest in metabolomics. The Latin America Metabolomics market is developing at an exceptionally rapid speed.

The metabolomics market in the Middle East & Africa is boosting due to factors like the emerging recognition of metabolomics in customized medicines. The expanding biotech innovative work and pharmaceutical consumption prompt persistent headways in innovation and spelling development for the worldwide metabolomics market. The unexplored markets in rising countries will goad new development open doors for market players. Further, the requirement for precisely qualified specialists and the lack of the same limits the expansion of the metabolomics market. The Middle East and Africa's Metabolomics market are evolving rapidly.


Some of the prominent companies playing a significant role in the global metabolomics market profiled in the report are Agilent Technologies, Inc. (U.S.), Human Metabolome Technologies, Inc. (Japan), Thermo Fisher Scientific, Inc. (U.S.), LECO Corporation (U.S.), Bruker Corporation (U.S.), Shimadzu Corporation (Japan), Metabolon Inc. (U.S.), Danaher Corporation (U.S.), Biocrates Life Sciences AG (Austria), and Waters Corporation (U.S.)


  • In April 2019, Agilent Company launched new products for the laboratories associated with metabolomics research, food testing, environmental screening, and various analytical pursuits. Products are designed mainly for improving the efficiency of analytical and business outcomes.
  • Metabolon Inc. has expanded its services and product portfolio regarding metabolomics by acquiring Metabolomic Discoveries GmbH in 2017.
  • Murdoch University entered into a strategic collaboration with Bruker Company in September 2019. The primary objective of this collaboration is to develop phenomics for the diagnosis of diseases and enhance personalized health.


This research report on the global metabolomics market has been segmented and sub-segmented based on the product, technology, and region.


By Product

  • Metabolomic Instruments                               
    • Separation Techniques   
      • Gas Chromatography (GC)
      • Capillary Electrophoresis (CE)
      • High-performance Liquid Chromatography (HPLC)
      • Ultra-performance Liquid Chromatography (UPLC)
    • Detection Tools 
      • Mass Spectrometry
      • Nuclear Magnetic Resonance Spectroscopy
      • Surface-Based Mass Analysis
  • Metabolomics Bioinformatics Tools and Services                  
    • Bioinformatics Tools & Databases              
    • Bioinformatics Services

By Indication

  • Cancer
  • Cardiovascular Disorders
  • Inborn errors
  • Neurological Errors
  • Other Indications

By Application

  • Nutrigenomics
  • Toxicology
  • Biomarker & Drug Discovery
  • Functional Genomics
  • Personalized Medicine
  • Other Applications

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • The Middle East and Africa

Please wait. . . . Your request is being processed

Frequently Asked Questions

What is the current size of the metabolomics market?

The global metabolomics market size was worth USD 2506 million in 2023.

What are the key drivers of the metabolomics market?

The growing demand for personalized medicine, growing research in the field of metabolomics, the rising prevalence of chronic diseases, and advancements in technology for metabolomics research are boosting the growth of the metabolomics market.

Who are the key players in the metabolomics market?

Agilent Technologies, Inc., Danaher Corporation, Thermo Fisher Scientific, Inc., Shimadzu Corporation, Waters Corporation, Bruker Corporation, and Metabolon, Inc. are some of the noteworthy companies in the global metabolomics market.

What are the challenges facing the metabolomics market?

The complexity of metabolomics data, lack of standardization in data analysis and interpretation, high costs of instruments and technologies, and the need for skilled professionals in metabolomics research are key challenges to the metabolomics market.

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1800

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample